What is the BiotechSign catalyst score for MRNA?

MRNA currently has a BiotechSign catalyst score of 46/100 and grade D. Scores combine FDA, clinical trial, insider, dilution, sentiment, short interest, and convergence signals.

What signals does BiotechSign track for MRNA?

BiotechSign tracks 0 active signals for MRNA, including 0 PDUFA signals, 0 insider buying signals, and 0 clinical trial signals when available.

When was the MRNA catalyst page updated?

This MRNA page was refreshed from BiotechSign data on 2026-07-19.

You have used your free lookups for today

Upgrade to BiotechSign Pro for unlimited company access, full signal history, watchlist alerts, and 125+ PDUFA dates.

Upgrade to Pro →← Back to screener

← Back to Screener

MRNA — Moderna Inc

Moderna Inc

mRNA TherapeuticsScore: 46/100Full Profile

What is the current MRNA catalyst setup?

MRNA is tracked by BiotechSign with a current catalyst score of 46/100 and grade D. The page summarizes 0 active signals, including 0 PDUFA, 0 insider buying, and 0 clinical trial signals, with data refreshed on 2026-07-19.

Company SnapshotUpdated 2026-07-19

As of 2026-07-19, Moderna Inc (MRNA) has a BiotechSign Catalyst Score of 46/100, rated D. The company has 0 active signals tracked by BiotechSign. BiotechSign scores combine FDA pipeline data, clinical trial activity, SEC insider filings, dilution risk, and sentiment analysis into a single catalyst grade.

This data is for informational purposes only and does not constitute financial or medical advice. Biotech and pharmaceutical stocks carry extreme risk, including binary FDA outcomes that can result in total loss. Always conduct your own due diligence. Source: BiotechSigns (biotechsign.com).

Analyst Summary

Verified 2026-04-11

Moderna Inc (MRNA) is the lead sponsor of 31 active clinical trials listed on ClinicalTrials.gov^[5], including 4 Phase 3^[1], 15 Phase 2^[2], 17 Phase 1^[3], 3 Phase 4^[4].

Trial NCT07117487^[6] evaluates mRNA-1345 in Respiratory Syncytial Virus with a target enrollment of 507 participants. Trial NCT06592794^[7] evaluates mRNA-1403 in Acute Gastroenteritis with a target enrollment of 37864 participants. Trial NCT06067230^[8] evaluates mRNA-1345 in Respiratory Syncytial Virus with a target enrollment of 1153 participants.

MRNA has 1 Form 4 insider filing recorded at the SEC in the past 30 days^[9].

Sources

ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov · NCT07117487 (2026-01-30) ↗
ClinicalTrials.gov · NCT06592794 (2026-02-25) ↗
ClinicalTrials.gov · NCT06067230 (2025-08-08) ↗
SEC EDGAR · 0001682852 (2026-04-11) ↗

Not financial advice. BiotechSign scores are for informational purposes only and do not constitute investment recommendations. Always do your own due diligence before making investment decisions.